Research Summary

Dr. Winger’s research is focused on advancing precision medicine to improve therapeutics and outcomes for patients with cancer and other blood diseases. Her research has two main focuses: 1) understanding mutations in kinases so that we can expand the use of targeted therapies and match the right drug to the right patient, and 2) developing precision dosing strategies to give every patient the right amount of drug for their body.

Education

Yale University, New Haven, CT, BA, 2001, Chemistry
University of California, San Francisco, CA, PhD, 2008, Chemistry & Chemical Biology
University of California, San Francisco, CA, MD, 2011, Medicine
University of California, San Francisco, CA, Residency, 2014, Pediatrics
University of California, San Francisco, CA, Fellowship, 2018, Pediatric Hem/Onc
University of Maryland, Baltimore (Online), 2019, Pharmacometrics

Honors & Awards

  • 1999
    Pfizer Synthetic Organic Chemistry Undergraduate Summer Research Fellowship
  • 2000
    Richter Summer Fellowship, Yale University
  • 2001
    Honors in Chemistry, Magna Cum Laude, Yale University
  • 2001 - 2002
    Fulbright Graduate Student Award, Fulbright Association
  • 2007 - 2008
    University of California Cancer Research Coordinating Committee Fellowship, University of California
  • 2015
    Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research
  • 2017 - 2020
    St. Baldrick's Foundation Fellowship Award, St. Baldrick's Foundation
  • 2017 - 2020
    Frank A. Campini Foundation Award, Frank A. Campini Foundation
  • 2020 - 2021
    Mary Anne Koda-Kimble Award for Innovation, UCSF
  • 2020 - 2021
    Resource Allocation Program Grant (co-PI), UCSF
  • 2020 - 2021
    Helen Diller Family Comprehensive Cancer Center Junior Clinical Investigator Award, UCSF

Selected Publications

  1. Winger BA, Ajayi A, Vichinsky E. Diagnosis and Treatment of Alpha Thalassemia Major. Hemoglobin. 2025 Jan; 49(1):3-9.  View on PubMed
  2. Dvorak CC, Temple WC, Cisneros GS, Chu J, Winestone LE, Higham CS, Shimano KA, Kharbanda S, Avagyan S, Pauerstein P, Huang JN, Cheng G, Waters E, Winger BA, Cowan MJ, Long-Boyle JR. Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning. Transplant Cell Ther. 2025 Apr; 31(4):259.e1-259.e15.  View on PubMed
  3. Marinoff AE, Thrall A, Aaronson K, Braun BS, Castellanos M, Chu J, Hermiston M, Huang BJ, Levinson A, Southworth E, Winger BA, Olshen A, Stieglitz E. Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. Pediatr Blood Cancer. 2025 Mar; 72(3):e31528.  View on PubMed
  4. Paolino J, Dimitrov B, Apsel Winger B, Sandoval-Perez A, Rangarajan AV, Ocasio-Martinez N, Tsai HK, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Polonen P, Dilig A, Gotti G, Kavanagh J, Adhav AA, Gow S, Tsai J, Li Y, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Tasian SK, Cooper SL, Cooper TM, Hijiya N, Sulis ML, Shukla NN, Magee JA, Mullighan CG, Burke MJ, Luskin MR, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pikman Y. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Clin Cancer Res. 2023 11 14; 29(22):4613-4626.  View on PubMed
  5. Apsel Winger B, Devine WP, Hsiao EC, Zapala M, Van Ziffle J, Gupta N, Frieden IJ, Shimano KA. EML4::ALK fusions in complex lymphatic malformations. Pediatr Blood Cancer. 2023 Jun 28; e30516.  View on PubMed
  6. Sandoval-Pérez A, Winger BA, Jacobson MP. Correction to "Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations". J Chem Theory Comput. 2023 Jan 10; 19(1):376.  View on PubMed
  7. Sandoval-Pérez A, Winger BA, Jacobson MP. Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations. J Chem Theory Comput. 2022 Oct 11; 18(10):6251-6258.  View on PubMed
  8. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. J Chromatogr Open. 2022 Nov; 2.  View on PubMed
  9. Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Apsel Winger B. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. J Clin Pharmacol. 2022 07; 62(7):873-882.  View on PubMed
  10. Apsel Winger B, Long SE, Brooks J, Gupta AO, Dvorak CC, Long-Boyle JR. A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults. Front Pediatr. 2021; 9:713091.  View on PubMed
  11. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439.  View on PubMed
  12. Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, Dvorak CC, Long-Boyle J. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transplant Cell Ther. 2021 03; 27(3):258.e1-258.e6.  View on PubMed
  13. Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Front Pharmacol. 2020; 11:888.  View on PubMed
  14. Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. J Clin Pharmacol. 2020 09; 60(9):1209-1219.  View on PubMed
  15. Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT. Cancer Res. 2019 08 15; 79(16):4283-4292.  View on PubMed
  16. Winger BA, Foy E, Sud SR, MacKenzie JD, Pua HH, Lau AH, Heyman MB, Laszik Z, Tureen J. Mycobacterium bovis Enterocolitis in an Immunocompromised Host. J Pediatr Gastroenterol Nutr. 2016 07; 63(1):e17-9.  View on PubMed
  17. Apsel Winger B, Shah NP. PPARγ: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411.  View on PubMed
  18. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009 Feb 10; 7(2):e38.  View on PubMed
  19. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov; 4(11):691-9.  View on PubMed
  20. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008 Aug 12; 14(2):180-92.  View on PubMed

Go to UCSF Profiles, powered by CTSI